 |
|
Around-the-Clock, Controlled-Release Oxycodone Therapy for Osteoarthritis-Related Pain
Placebo-Controlled Trial and Long-term Evaluation
Sanford H. Roth, MD;
Roy M. Fleischmann, MD;
Francis X. Burch, MD;
Frederick Dietz, MD;
Barry Bockow, MD;
Ronald J. Rapoport, MD;
Joel Rutstein, MD;
Peter G. Lacouture, PhD
Arch Intern Med. 2000;160:853-860.
Background Although opioid analgesics have well-defined efficacy and safety in treatment of chronic cancer pain, further research is needed to define their role in treatment of chronic noncancer pain.
Objective To evaluate the effects of controlled-release oxycodone (OxyContin tablets) treatment on pain and function and its safety vs placebo and in long-term use in patients with moderate to severe osteoarthritis pain.
Methods One hundred thirty-three patients experiencing persistent osteoarthritis-related pain for at least 1 month were randomized to double-blind treatment with placebo (n = 45) or 10 mg (n = 44) or 20 mg (n = 44) of controlled-release oxycodone every 12 hours for 14 days. One hundred six patients enrolled in an open-label, 6-month extension trial; treatment for an additional 12 months was optional.
Results Use of controlled-release oxycodone, 20 mg, was superior (P<.05) to placebo in reducing pain intensity and the interference of pain with mood, sleep, and enjoyment of life. During long-term treatment, the mean dose remained stable at approximately 40 mg/d after titration, and pain intensity was stable. Fifty-eight patients completed 6 months of treatment, 41 completed 12 months, and 15 completed 18 months. Common opioid side effects were reported, several of which decreased in duration as therapy continued.
Conclusions Around-the-clock controlled-release oxycodone therapy seemed to be effective and safe for patients with chronic, moderate to severe, osteoarthritis-related pain. Effective analgesia was accompanied by a reduction in the interference of pain with mood, sleep, and enjoyment of life. Analgesia was maintained during long-term treatment, and the daily dose remained stable after titration. Typical opioid side effects were reported during short- and long-term therapy.
From Arthritis Center Ltd, Phoenix, Ariz (Dr Roth); Rheumatology Associates, Metroplex Clinical Research Center, Dallas, Tex (Dr Fleischmann); Rockford Clinic, Rockford, Ill (Dr Dietz); Truesdale Clinic, Fall River, Mass (Dr Rapoport); Arthritis Diagnostic and Treatment Center, San Antonio, Tex (Dr Rutstein); and Purdue Pharma LP, Norwalk, Conn (Dr Lacouture). Dr Burch is in private practice in San Antonio, and Dr Bockow is in private practice in Seattle, Wash. Dr Roth is now with ArthroCare, Arthritis Care & Research, PC, Phoenix. Dr Lacouture is employed by Purdue Pharma LP, the manufacturer of controlled-release oxycodone tablets (OxyContin tablets).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Impact of opioid rescue medication for breakthrough pain on the efficacy and tolerability of long-acting opioids in patients with chronic non-malignant pain
Devulder et al.
Br J Anaesth 2009;103:576-585.
ABSTRACT
| FULL TEXT
A Comparison of Long- and Short-Acting Opioids for the Treatment of Chronic Noncancer Pain: Tailoring Therapy to Meet Patient Needs
Argoff and Silvershein
Mayo Clin Proc. 2009;84:602-612.
ABSTRACT
| FULL TEXT
The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy
Van Zee
AJPH 2009;99:221-227.
ABSTRACT
| FULL TEXT
Prescription OxyContin Abuse Among Patients Entering Addiction Treatment
Carise et al.
Am. J. Psychiatry 2007;164:1750-1756.
ABSTRACT
| FULL TEXT
Pain Management in Elderly Patients
Hix
Journal of Pharmacy Practice 2007;20:49-63.
ABSTRACT
Prescription Drug Dependence and Evolving Beliefs About Chronic Pain Management
Streltzer and Johansen
Am. J. Psychiatry 2006;163:594-598.
FULL TEXT
Clinical trials studying pharmacotherapy and psychological treatments alone and together
Haythornthwaite
Neurology 2005;65:S20-S31.
ABSTRACT
| FULL TEXT
Controlled-Release Oxycodone
Levine and Burdick
J Am Acad Orthop Surg 2005;13:1-4.
FULL TEXT
Efficacy and Tolerability of Cancer Pain Management with Controlled-release Oxycodone Tablets in Opioid-naive Cancer Pain Patients, Starting with 5 mg Tablets
Koizumi et al.
Jpn J Clin Oncol 2004;34:608-614.
ABSTRACT
| FULL TEXT
Treatment Options in Knee Osteoarthritis: The Patient's Perspective
Fraenkel et al.
Arch Intern Med 2004;164:1299-1304.
ABSTRACT
| FULL TEXT
Opioid Therapy for Chronic Pain
Ballantyne and Mao
NEJM 2003;349:1943-1953.
FULL TEXT
Opioids and chronic pain
Gardner-Nix
CMAJ 2003;169:904-904.
FULL TEXT
Treatment of Chronic Pain
Ghafoor
Journal of Pharmacy Practice 2003;16:249-260.
ABSTRACT
Management of Painful Conditions in the Elderly
Ghafoor
Journal of Pharmacy Practice 2003;16:276-283.
ABSTRACT
Pain Management in Patients With Osteoarthritis
Egener
JAMA 2003;290:36-36.
FULL TEXT
Controlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trial
Gimbel et al.
Neurology 2003;60:927-934.
ABSTRACT
| FULL TEXT
|
